Tenaya Therapeutics (TNYA)
(Real Time Quote from BATS)
$1.99 USD
-0.01 (-0.50%)
Updated Sep 16, 2024 01:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
TNYA 1.99 -0.01(-0.50%)
Will TNYA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for TNYA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TNYA
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
TNYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for TNYA
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA), Tenaya Therapeutics (TNYA) and PepGen Inc. (PEPG)
Tenaya Therapeutics: A Buy Recommendation Based on Clinical Progress and Financial Fortitude
Buy Rating Affirmed for Tenaya Therapeutics: Strong Clinical Progress and Strategic Financial Positioning
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024